4-18eth (@pauesol) 's Twitter Profile
4-18eth

@pauesol

Billionaire Eventually ! Sapiosexual!

ID: 1141071771321405441

calendar_today18-06-2019 19:54:45

30 Tweet

11 Followers

138 Following

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Treatment landscape for resectable NSCLS is quickly changing. Discussion/group effort by led Arthi Sridhar Ivy Riano, M.D. Arpan Patel to reiterate the current SoC! Patrick Forde thank you for ICER table! 🙏🏽🙏🏽 #lcsm #ASCODailyNews ASCO #OncTwitter #ASCO24 #MedTwitter

Treatment landscape for resectable NSCLS is quickly changing. Discussion/group effort by led <a href="/ASridharMD/">Arthi Sridhar</a> <a href="/IvyLorena_Md/">Ivy Riano, M.D.</a> <a href="/ArpanAshokPatel/">Arpan Patel</a> to reiterate the current SoC! 

<a href="/FordePatrick/">Patrick Forde</a> thank you for ICER table! 🙏🏽🙏🏽

#lcsm #ASCODailyNews <a href="/ASCO/">ASCO</a> #OncTwitter #ASCO24 #MedTwitter
Jordi Remon (@jordiremon) 's Twitter Profile Photo

1stG KRAG12Ci (sotirasib and adagrasib) reached a plateau RR~35% PFS ~6 mo. Monotherapy not enough. Next step is moving to move to 1st L in combo with immuno or cetuximab such as fulzerasib 600 mg BID cetux. 500 mg/m2 Q2W➡️ RR 81% Future of KRAS strategy is combo approach #ASCO24

1stG KRAG12Ci (sotirasib and adagrasib) reached a plateau RR~35% PFS ~6 mo. Monotherapy not enough. Next step is moving to move to 1st L in combo with immuno or cetuximab such as fulzerasib 600 mg BID cetux. 500 mg/m2 Q2W➡️ RR 81% Future of KRAS strategy is combo approach #ASCO24
Lauren Averett Byers, MD (@laurenbyersmd) 's Twitter Profile Photo

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. MD Anderson Cancer Center Thank you to the study team and all of our investigators, patients and families. ASCO #ASCO24

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI?  Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> Thank you to the study team and all of our investigators, patients and families. <a href="/ASCO/">ASCO</a> #ASCO24
Eric K. Singhi, MD (@lungoncdoc) 's Twitter Profile Photo

IASLC Highlights: 1️⃣Multidisciplinary approach for rNSCLC 2️⃣Biomarker testing 3️⃣Preference for neoadjuvant chemoIO in stage 3 4️⃣Equipoise on stage 2 management (adjuvant v neoadjuvant/periop) 5️⃣Preference for adjuvant targeted tx for EGFR/ALK alterations Jonathan Spicer MD PhD #lcsm